DK116870B - Analogifremgangsmåde til fremstilling af terapeutisk virksomme 11β,21-dihydroxy-3,20-dioxo- eller 21-hydroxy-3,11,20-trioxo-pregna-1,4-dien-(17α 16&alpha,-d)-2'metyloxazoliner eller 21-estere deraf. - Google Patents

Analogifremgangsmåde til fremstilling af terapeutisk virksomme 11β,21-dihydroxy-3,20-dioxo- eller 21-hydroxy-3,11,20-trioxo-pregna-1,4-dien-(17α 16&alpha,-d)-2'metyloxazoliner eller 21-estere deraf.

Info

Publication number
DK116870B
DK116870B DK204266AA DK204266A DK116870B DK 116870 B DK116870 B DK 116870B DK 204266A A DK204266A A DK 204266AA DK 204266 A DK204266 A DK 204266A DK 116870 B DK116870 B DK 116870B
Authority
DK
Denmark
Prior art keywords
methyloxazolines
pregna
trioxo
dioxo
dihydroxy
Prior art date
Application number
DK204266AA
Other languages
Danish (da)
English (en)
Inventor
G Nathansohn
G Winters
Original Assignee
Lepetit Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lepetit Spa filed Critical Lepetit Spa
Publication of DK116870B publication Critical patent/DK116870B/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027Azides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/0025Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16
    • C07J7/0035Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16 by a hydroxy group free esterified or etherified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036Nitrogen-containing hetero ring
    • C07J71/0057Nitrogen and oxygen
    • C07J71/0068Nitrogen and oxygen at position 16(17)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Machines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK204266AA 1965-04-22 1966-04-21 Analogifremgangsmåde til fremstilling af terapeutisk virksomme 11β,21-dihydroxy-3,20-dioxo- eller 21-hydroxy-3,11,20-trioxo-pregna-1,4-dien-(17α 16&alpha,-d)-2'metyloxazoliner eller 21-estere deraf. DK116870B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB17027/65A GB1077392A (en) 1965-04-22 1965-04-22 New steroids
GB3586565 1965-08-20

Publications (1)

Publication Number Publication Date
DK116870B true DK116870B (da) 1970-02-23

Family

ID=26252388

Family Applications (2)

Application Number Title Priority Date Filing Date
DK204266AA DK116870B (da) 1965-04-22 1966-04-21 Analogifremgangsmåde til fremstilling af terapeutisk virksomme 11β,21-dihydroxy-3,20-dioxo- eller 21-hydroxy-3,11,20-trioxo-pregna-1,4-dien-(17α 16&alpha,-d)-2'metyloxazoliner eller 21-estere deraf.
DK204166AA DK117631B (da) 1965-04-22 1966-04-21 Fremgangsmåde til fremstilling af 20-oxopregnan-, 20-oxo-4-pregnen- eller 20-oxo-5(6)-pregnen-(17α, 16α-d)-oxazoliner.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK204166AA DK117631B (da) 1965-04-22 1966-04-21 Fremgangsmåde til fremstilling af 20-oxopregnan-, 20-oxo-4-pregnen- eller 20-oxo-5(6)-pregnen-(17α, 16α-d)-oxazoliner.

Country Status (15)

Country Link
US (2) US3413286A (es)
AT (2) AT260440B (es)
BE (2) BE679821A (es)
BR (2) BR6678805D0 (es)
CH (2) CH471833A (es)
DE (3) DE1793662C3 (es)
DK (2) DK116870B (es)
ES (1) ES325755A1 (es)
FI (2) FI44906C (es)
FR (1) FR5645M (es)
GB (1) GB1077392A (es)
IL (2) IL25494A (es)
NL (3) NL6605174A (es)
NO (2) NO127346B (es)
SE (2) SE323675B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1119081A (en) * 1966-01-11 1968-07-10 Lepetit Spa New steroids
IT1141930B (it) * 1980-04-28 1986-10-08 Lepetit Spa Esteri idrosolubili di steroido-ossazoli e loro composizioni farmaceutiche
IT1134455B (it) * 1980-11-26 1986-08-13 Lepetit Spa Procedimento per la preparazione di derivati 16alfa-idrossi-17alfa-aminopregnanici
CA2537185A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
JP2009512677A (ja) * 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ホスホジエステラーゼタイプiv阻害剤の組成物
RU2008119323A (ru) 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Фармацевтические композиции мускаринового рецептора
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CN101177443B (zh) * 2006-11-09 2011-08-03 天津药业研究院有限公司 新的甾体化合物及其应用
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
CA2680625C (en) 2007-03-14 2016-02-23 Ranbaxy Laboratories Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2874154A (en) * 1954-10-15 1959-02-17 Syntex Sa Process for the production of 20-keto-21-iodo steroids
US2923721A (en) * 1955-12-13 1960-02-02 Lab Francais Chimiotherapie Method of preparing 3-keto delta1, 4 steroids
DE1223376B (de) * 1963-12-14 1966-08-25 Hoechst Ag Verfahren zur Herstellung von 17alpha-Cyan-16alpha-hydroxy-steroiden der Pregnanreihe
US3349084A (en) * 1965-05-17 1967-10-24 Upjohn Co Steroidal [16, 17-d]-2'-isoxazolines of the pregnane series

Also Published As

Publication number Publication date
IL25493A (en) 1969-12-31
DE1568950A1 (de) 1970-11-26
US3413286A (en) 1968-11-26
FI44906B (es) 1971-11-01
SE323675B (es) 1970-05-11
ES325755A1 (es) 1967-02-16
CH453351A (fr) 1968-06-14
NO128152B (es) 1973-10-08
FR5645M (es) 1967-12-26
DE1793662C3 (de) 1973-11-08
DK117631B (da) 1970-05-19
AT265539B (de) 1968-10-10
US3436389A (en) 1969-04-01
DE1793662A1 (de) 1972-08-03
BE679821A (es) 1966-10-03
DE1568951A1 (de) 1970-06-18
BE679820A (es) 1966-10-03
CH471833A (fr) 1969-04-30
BR6678805D0 (pt) 1973-09-18
BR6679615D0 (pt) 1973-10-23
IL25494A (en) 1970-03-22
FI44905C (fi) 1972-02-10
NL6605375A (es) 1966-10-24
NL128816C (es)
GB1077392A (en) 1967-07-26
DE1793662B2 (de) 1973-04-19
SE323674B (es) 1970-05-11
FI44906C (fi) 1972-02-10
NO127346B (es) 1973-06-12
FI44905B (es) 1971-11-01
AT260440B (de) 1968-03-11
NL6605174A (es) 1966-10-24

Similar Documents

Publication Publication Date Title
DK116128B (da) Fremgangsmåde til fremstilling af terapeutisk virksomme 17α-(alkanoyloxy eller cycloalkanoyloxy)-21-(alkanoyloxy eller cycloalkanoyloxy)-16β-methyl-9α-halogen-11β-hydroxy-Δ<1,4>-pregnadien-3,20-dioner.
DK116870B (da) Analogifremgangsmåde til fremstilling af terapeutisk virksomme 11β,21-dihydroxy-3,20-dioxo- eller 21-hydroxy-3,11,20-trioxo-pregna-1,4-dien-(17α 16&alpha,-d)-2'metyloxazoliner eller 21-estere deraf.
DK129835B (da) Analogifremgangsmåde til fremstilling af 2-chlor-6α-fluor-16α-methyl-pregna-1,4-dien-3,20-dioner.
DK117563B (da) Analogifremgangsmåde til fremstilling af 17α,21-(1'-alkyl-1'-alkoxy-methylendioxy)-11β-hydroxy-9-α-halogen-16β-methyl-1,4-pregnadien-3,20-dioner.
DK128352B (da) Analogifremgangsmåde til fremstilling af 9α-fluor-11β-hydroxypregna-1,4-dien-3,20-dion-[17α,16α-d]-oxazolidinoxaziner.
DK130991B (da) Fremgangsmåde til fremstilling af 16beta-metyl-9alfa-fluor-11beta-17alfa,21-trihydroxy-1,4-pregnadien-3,20-dion eller dets 21-acylater.
DK120190B (da) Analogifremgangsmåde til fremstilling af terapeutisk aktive 17-estere af 9α,11β-dihalogen-16α-alkyl-Δ<1,4>-pregnadien-17α,21-diol-3,20-dioner.
DK129039B (da) Fremgangsmåde til fremstilling af 11β,16α17α21-tetrahydroxy-pregna-1,4-dien-3,20-dioner eller de tilsvarende 16,17-acetonider.
DK117894B (da) Analogifremgangsmåde til fremstilling af 17aα-metyl-17aβ-hydroksy-D-homo-Δ<4,6>-androstadien-3,17-dioner eller deres estere.
DK120337B (da) Fremgangsmåde til fremstilling af terapeutisk aktive 3-keto-6-halogen-9β10α-Δ<4,6>-steroiddiener af androstan- eller pregnanrækken.
DK131474B (da) Analogifremgangsmåde til fremstilling af 9alfa-halogen-11beta, 17alfa, 21-trihydroxy-16beta-metylpregna-1,4-dien-3,20-dion-21-adamantan-1'-karboxylater.
DK114690B (da) Fremgangsmåde til fremstilling af terapeutisk virksomt 17α-ethinyl-Δ<1,3,5(10)>-østratrien-3,16α,17β-triol eller estere eller ethere deraf.
DK120701B (da) Analogifremgangsmåde til fremstilling af terapeutisk virksomme 17β-tetrahydropyranylethere af Δ<1,3,5(10)>-østratrien-3-ol-eller 3-ethere eller 3-estere deraf.
DK126111B (da) Fremgangsmåde til fremstilling af Δ<5,10>-steroider med cyclopentanoperhydrophenanthrenstruktur.
DK114060B (da) Fremgangsmåde til fremstilling af terapeutisk virksomme 1,2β-metylensteroider af androstan- eller 9-norandrostanrækken.
DK112235B (da) Fremgangsmåde til fremstilling af terapeutisk virksomme 21-dicyclohexylmethylcarbonater af 21-hydroxy-Δ<4>-pregnen-17α-ol-3,20-dioner.
DK122453B (da) Analogifremgangsmåde til fremstilling af 21-estere af 6α,9α-dihalogen-16α-methyl-Δ<1,4>-pregnadien-11β,21-diol-3,20-dioner.
DK113146B (da) Fremgangsmåde til fremstilling af terapeutisk virksomme 6-halogen-1α,2α-methylen-16α-methyl-&Delta<4,6>-pregnadien-17α-ol-3,20-dioner eller deres 17-estere.
DK127924B (da) Analogifremgangsmåde til fremstilling af 7α-methyl-3,16α,17β-trihydroxy-Δ1,3,5(10)-estratrien.
DK118556B (da) Analogifremgangsmåde til fremstilling af 16α-methyl-9α-chlor-Δ<1,4>-pregnadien-11β,21-diol-3,20-dioner eller 21-estere deraf.
DK120746B (da) Analogifremgangsmåde til fremstilling af 4-klor-1,2α-metylen-Δ<4,6>-pregnadien-17α-ol-3,20-dion eller 17-estere deraf.
DK105065C (da) Fremgangsmåde til fremstilling af 16α,17α-acetaler eller -ketaler af 3-oxo-16α,17α-dihydroxy-19-nor-4-pregnener eller 3-oxo-16α,17α-dihydroxy-19-nor-5(10)-pregnener.
DK130646B (da) Analogifremgangsmåde til fremstilling af 17- og/eller 21-alkanoyloxy-11beta-klor-16beta-metylpregna-1,4-dien-3,20-dioner.
DK111615B (da) Fremgangsmåde til fremstilling af 6α,9α-difluor-16α-metyl-Δ<1,4>-pregnadien-11β,21-diol-3,20-dion eller estere deraf.
DK131114B (da) Analogifremgangsmåde til fremstilling af terapeutisk virksomme 17alfa-halogenalkynylgona-4,9-dien-3-oner eller de tilsvarende D-homo-forbindelser.